Search Results
| Year | ID | Type | Category | Title | Authors |
|---|
| 2021 | DMT27 | Poster | Disease-modifying Therapy |
Acapella: Hypogammaglobulinemia and JCV Status in Ocrelizumab-Treated Patients, Year Four Data |
Elizabeth A Douglas, MPH, Rosie M Jungquist, B.S., Andrew J Bouley, M.D., Joshua D Katz, M.D. and Ellen S Lathi, M.D., The Elliot Lewis Center for Multiple Sclerosis Care, Wellesley, MA |
| 2021 | DMT28 | Poster | Disease-modifying Therapy |
Real-World Cost of Care, Treatment Completion and Site of Care Cost for Patients with Multiple Sclerosis Initiating Infused Disease-Modifying Therapies |
Enrique Alvarez, MD, PhD, MSCI1, Kavita V Nair, PhD1, Hiangkiat Tan, MS2, Kapil Rathi, PhD2, Nicole Gabler, PhD2 and Chinmay Deshpande, PhD, BPharm3, (1)Rocky Mountain Multiple Sclerosis Center at the University of Colorado, Aurora, CO, (2)HealthCore Inc., Wilmington, DE, (3)Novartis Pharmaceuticals Corporation, East Hanover, NJ |
| 2021 | DMT29 | Poster | Disease-modifying Therapy |
Real-Life Experience with Ocrelizumab in Older Patients at an Academic MS Center |
Evan Luxenberg, MD1, Gloria von Geldern, MD1,2, Meghan C Romba, MD1,2, Yujie Wang, MD1,2, Deborah Gallaro, R.Ph.2, Bren Hammond, RN, BSN, MSCN2, Jennie Toro, RN2, Wendy Durand, RN, BSN2, Melissa F Kennedy, RN, C-MSCN2, Samantha Kelly, RN2, Sarika Vyasarayani, RN, BSN2 and Annette Wundes, MD1,2, (1)Neurology, University of Washington, Seattle, WA, (2)University of Washington MS Center, Seattle, WA |
| 2021 | DMT30 | Poster | Disease-modifying Therapy |
Francis C Staskon, PhD, MS1, Heather Kirkham, PhD, MPH1 and Kathleen Love, RN, BA2, (1)HealthCare Analytics, Research & Reporting, Walgreen, Co., Deerfield, IL, (2)Clinical Program Manager, AllianceRx Walgreens Prime, Deerfield, IL |
| 2021 | DMT31 | Poster | Disease-modifying Therapy |
Adherence to Multiple Sclerosis Disease Modifying Therapies Using Pharmacy Quality Alliance Criteria and Medical Costs or Hospitalizations in an Administrative Database. |
Francis C Staskon, PhD, MS1, Heather Kirkham, PhD, MPH1 and Kathleen Love, RN, BA2, (1)HealthCare Analytics, Research & Reporting, Walgreen, Co., Deerfield, IL, (2)Clinical Program Manager, AllianceRx Walgreens Prime, Deerfield, IL |
| 2021 | DMT33 | Poster | Disease-modifying Therapy |
Characterization of Peripheral Immune Cell Dynamics and Repopulation Patterns in the First 12 Months of Cladribine Tablets Treatment: Magnify-MS Study |
| 2021 | DMT34 | Poster | Disease-modifying Therapy |
Jacob A Sloane, MD PhD1, Kyle E. Smoot, MD2, Bianca Weinstock-Guttman, MD3, Sibyl Wray, MD4, Miguel Rosales, MSc5, Sai L. Shankar, PhD5, Justin Bohn, ScD5, Catherine Miller, PharmD, MPH5, Jordan Messer, PharmD5, Jason P. Mendoza, PhD5 and James B. Lewin, PharmD5, (1)Department of Neurology, Beth Israel Deaconess Medical Center, Boston, MA, (2)Providence Multiple Sclerosis Center, Providence Brain and Spine Institute, Portland, OR, (3)Jacobs Multiple Sclerosis Center for Treatment and Research, Jacobs School of Medicine and Biomedical Science, University at Buffalo, Buffalo, NY, (4)Hope Neurology, Knoxville, TN, (5)Biogen, Cambridge, MA |
| 2021 | DMT35 | Poster | Disease-modifying Therapy |
COVID-19 Prevention Behaviors and PCR Testing Among MS Patients Treated with Different Dmts: Survey Data from MS Paths |
Jakai Nolan, DO, MPH1, Jacqueline Nicholas, MD, MPH1, Andrew Smith, MD1, Irene Koulinska, MD, ScD2, Arman Altincatal, MS2, Cyndi Grossman, PhD2, Scott Husak, Statistical Programmer3, Kedar Mahajan, MD, PhD3, Robert A Bermel, MD4, Jeff Cohen, MD3 and Brandon Moss, MD5, (1)OhioHealth, Columbus, OH, (2)Biogen, Cambridge, MA, (3)Cleveland Clinic, Cleveland, OH, (4)Mellen Center for MS, Cleveland Clinic, Cleveland, OH, (5)Mellen Center for Multiple Sclerosis, Cleveland Clinic, Cleveland, OH |
| 2021 | DMT36 | Poster | Disease-modifying Therapy |
Real World Experience with Systemic Injection Reactions to Ofatumumab |
John F Kramer, PA-C, Neurology, St Thomas Medical Partners, Nashville, TN |
| 2021 | DMT37 | Poster | Disease-modifying Therapy |
Updated Post-Approval Safety of Cladribine Tablets in the Treatment of Multiple Sclerosis, with Particular Reference to Respiratory Viral Infections and COVID-19 |
Gavin Giovannoni, MD, PhD, Queen Mary University of London, London, United Kingdom, Joseph Berger, MD, FACP, FAAN, FANA, Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, Thomas P. Leist, MD, Comprehensive Multiple Sclerosis Center, Division of Clinical Neuroimmunology, Jefferson University, Philadelphia, PA, Dominic Jack, PhD, Merck KGaA, Darmstadt, Germany, Andrew Galazka, MD, Merck KGaA, Darmstadt, Germany, Aubonne, Switzerland, Axel Nolting, MD, Merck KGaA, Darmstadt, Germany, Darmstadt, Germany and Doris Damian, PhD, EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, a business of Merck KGaA, Darmstadt, Germany, Billerica, MA |
| 2021 | DMT38 | Poster | Disease-modifying Therapy |
Natalizumab: Management and Safety during the COVID-19 Pandemic |
| 2021 | DMT39 | Poster | Disease-modifying Therapy |
Characteristics and Outcomes By Employment and Education Status for Patients Treated with Peginterferon Beta-1a or Intramuscular Interferon Beta-1a |
Kathryn C Fitzgerald, ScD1, Carrie M Hersh, DO, MS2, Lana Zhovtis Ryerson, MD3, Ellen M Mowry, MD, MCR4, Shirley Liao, PhD5, Arman Altincatal, MS5 and Maria L Naylor, PhD5, (1)Johns Hopkins Medicine, Department of Neurology, Baltimore, MD, (2)Cleveland Clinic, Lou Ruvo Center for Brain Health, Las Vegas, NV, (3)NYU Grossman School of Medicine, Department of Neurology, New York, NY, (4)Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, (5)Biogen, Cambridge, MA |
| 2021 | DMT40 | Poster | Disease-modifying Therapy |
Real-World Safety and Effectiveness of Delayed-Release Dimethyl Fumarate in Relapsing Multiple Sclerosis Patients: Interim Results from Esteem |
| 2021 | DMT41 | Poster | Disease-modifying Therapy |
Analyses of the Effect of Baseline Age on the Efficacy and Safety of Siponimod in Patients with Active Secondary Progressive Multiple Sclerosis from the Expand Study |
Le H. Hua, MD1, Amit Bar-Or, MD2, Fred D. Lublin, MD3, Xiangyi Meng, PhD4, Gina Mavrikis Cox, PhD4, Bruce A.C. Cree, MD, PhD, MAS5 and Robert J. Fox, MD6, (1)Lou Ruvo Center for Brain Health, Las Vegas, NV, (2)Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, (3)Icahn School of Medicine at Mount Sinai, New York, NY, (4)Novartis Pharmaceuticals Corporation, East Hanover, NJ, (5)Department of Neurology, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, (6)Cleveland Clinic, Cleveland, OH |
| 2021 | DMT42 | Poster | Disease-modifying Therapy |
Assessing the Impact of Fingolimod Adherence on Relapse and Costs Using Marginal Structural Models |
Le H. Hua, MD1, Roshani Shah, MS2, Gina Mavrikis Cox, PhD2, Tim Bancroft, PhD3, Rachel Halpern, PhD3 and Miriam G. Cisternas, MA3, (1)Lou Ruvo Center for Brain Health, Las Vegas, NV, (2)Novartis Pharmaceuticals Corporation, East Hanover, NJ, (3)Health Economics and Outcomes Research, Optum, Eden Prairie, MN |
| 2021 | DMT43 | Poster | Disease-modifying Therapy |
Olikos Study Design: Exploring Maintained Ofatumumab Efficacy in Relapsing MS Patients Who Transition from Intravenous Anti-CD20 Therapy |
Le H Hua, MD1, Enrique Alvarez, MD, PhD, MSCI2, Roland G Henry, PhD3, Joel Brown, PhD, PharmD4, Elizabeth Camacho, MBA4, Xiangyi Meng, PhD4, Marina Ziehn, PhD5, Brandon Brown, PharmD4 and Benjamin M Greenberg, MD, MHS6, (1)Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, (2)Department of Neurology, University of Colorado, Aurora, CO, (3)UCSF Neurology, Weill Institute for Neurosciences, San Francisco, CA, (4)Novartis Pharmaceuticals Corporation, East Hanover, NJ, (5)Novartis Pharma AG, Basel, Switzerland, (6)Neurology & Neurotherapeutics – MS Clinic, UT Southwestern Medical Center, Dallas, TX |
| 2021 | DMT44 | Poster | Disease-modifying Therapy |
Incidence and Severity of Natalizumab Infusion-Related Reactions during Infusion and Postinfusion Observation |
Ling Jin, MD, Zheng Ren, PhD, Prabjot Hunjan, BSc, PgDip, Seth Levin, MD and Stephanie Licata, PhD, Biogen, Cambridge, MA |
| 2021 | DMT45 | Poster | Disease-modifying Therapy |
Dual Mode of Action of Siponimod in Secondary Progressive Multiple Sclerosis: A Hypothesis Based on the Relevance of Pharmacological Properties |
Marc Bigaud, PhD1, Frank Dahlke, MD1, Thomas Hach, MD1, Daniela Piani-Meier, PhD1 and Ralf Gold, MD2, (1)Novartis Pharma AG, Basel, Switzerland, (2)Department of Neurology, St Josef-Hospital, Ruhr-University Bochum, Bochum, Germany |
| 2021 | DMT46 | Poster | Disease-modifying Therapy |
Post-Approval Safety of Subcutaneous Interferon ?-1a in the Treatment of Multiple Sclerosis, with Particular Reference to Respiratory Viral Infections |
Mark S. Freedman, HBSc, MSc, MD, CSPQ, FANA, FAAN, FRCPC1, Hans Guehring, MD2, Zuzana Murgasova, MD2 and Dominic Jack, PhD2, (1)University of Ottawa, Department of Medicine and the Ottawa Hospital Research Institute, Ottawa, ON, Canada, (2)Merck KGaA, Darmstadt, Germany |
| 2021 | DMT47 | Poster | Disease-modifying Therapy |
Opportunities and Pitfalls in the Assessment of Brain Atrophy in Dimethyl Fumarate-Treated Relapsing Multiple Sclerosis Patients Using Real-World Data |
Mark Gudesblatt, MD1, Myassar Zarif, MD1, Barbara Bumstead, MS, ANP-C, MSCN1, Marijean Buhse, NP-C, PhD1, Olivia Kaczmarek, BS1, Jared Srinivasan, BS2, Nuno Barros, PhD3, Annemie Ribbens, PhD3, Wim Van Hecke, PhD3, Elise Digga, BA4, Jason P. Mendoza, PhD2 and Stephen Krieger, MD4, (1)South Shore Neurologic Associates, Patchogue, NY, (2)Biogen, Cambridge, MA, (3)icometrix, Leuven, Belgium, (4)Icahn School of Medicine at Mt. Sinai, New York, NY |
| 2021 | DMT48 | Poster | Disease-modifying Therapy |
Efficacy and Safety of Eculizumab in Patients with Neuromyelitis Optica Spectrum Disorder Previously Treated with Rituximab: Findings from Prevent |
Michael Levy, MD, PhD1,2, Achim Berthele, MD3, Ho Jin Kim, MD, PhD4, Kazuo Fujihara, MD5,6,7, Ichiro Nakashima, MD, PhD6,8, Celia Oreja-Guevara, MD9, Jacqueline Palace, DM10, Sean J Pittock, M.D.11, Murat Terzi, MD12, Natalia Totolyan, MD13, Shanthi Viswanathan, MRCP14, Kai-Chen Wang, MD, PhD15,16, Amy Pace, ScD17, Marcus Yountz, MD17, Diane Lawson, PharmD, RPh17, Eva Laudon-Meyer, MD PhD18 and Dean Wingerchuk, M.D.19, (1)Massachusetts General Hospital and Harvard Medical School, Boston, MA, (2)Johns Hopkins University, Baltimore, MD, (3)Klinikum rechts der Isar, School of Medicine, Technical University of Munich, Munich, Germany, (4)Research Institute and Hospital, National Cancer Center, Goyang, Korea, Republic of (South), (5)Southern TOHOKU Research Institute for Neuroscience (STRINS), Koriyama, Japan, (6)Tohoku University, Sendai, Japan, (7)Fukushima Medical University, Fukushima City, Japan, (8)Tohoku Medical and Pharmaceutical University, Sendai, Japan, (9)Hospital Universitario Clinico San Carlos, Madrid, Spain, (10)John Radcliffe Hospital, Oxford, United Kingdom, (11)Mayo Clinic, Rochester, MN, (12)Ondokuz Mayis University, Samsun, Turkey, (13)National Medical University, St Petersburg, Russian Federation, (14)Kuala Lumpur Hospital, Kuala Lumpur, Malaysia, (15)School of Medicine, National Yang Ming University, Taipei, Taiwan, (16)Cheng-Hsin General Hospital, Taipei, Taiwan, (17)Alexion Pharmaceuticals, Boston, MA, (18)Alexion Pharmaceuticals, Zurich, Switzerland, (19)Mayo Clinic, Scottsdale, AZ |
| 2021 | DMT49 | Poster | Disease-modifying Therapy |
Mitzi J Williams, MD1, Janine Robinson, MS2, Katarzyna Elliott-Maksymowicz, MSc2, Bianca Luscher, BS2 and Chinmay Deshpande, PhD, BPharm3, (1)Joi Life Wellness Group, LLC, Smyrna, GA, (2)W2O Group, Philadelphia, PA, (3)Novartis Pharmaceuticals Corporation, East Hanover, NJ |
| 2021 | DMT50 | Poster | Disease-modifying Therapy |
Alopecia in Multiple Scleoris Patients Treated with Disease Modifying Therapies |
Mokshal H Porwal, BSc, Medical College of Wisconsin, Milwaukee, WI, Amber Salter, PhD, Washington University School in St. Louis, St Louis, MO and Ahmed Z Obeidat, MD, PhD, Department of Neurology, Medical College of Wisconsin, Milwaukee, WI |
| 2021 | DMT51 | Poster | Disease-modifying Therapy |
Psoriasis in Multiple Sclerosis Patients Treated with Disease Modifying Therapies |
Mokshal H Porwal, BSc, Medical College of Wisconsin, Milwaukee, WI, Dhruvkumar Patel, BMSc, Arizona College of Osteopathic Medicine, Glendale, AZ, Michelle Maynard, PharmD, BCPS, Neurosciences, Froedtert and the Medical College of Wisconsin, Milwaukee, WI and Ahmed Z Obeidat, MD, PhD, Department of Neurology, Medical College of Wisconsin, Milwaukee, WI |
| 2021 | DMT52 | Poster | Disease-modifying Therapy |
Adherence and Persistence to Injectable Disease-Modifying Therapies Among Patients with Multiple Sclerosis Enrolled in US Commercial Plans |
Nicole Tsao, PhD, Shaobin Dong, MBA, Maria L Naylor, PhD, Qiang Hou, PhD and Mandakini Awasthy, MS, Biogen, Cambridge, MA |
| 2021 | DMT53 | Poster | Disease-modifying Therapy |
Multiple Sclerosis Patients Initiating Ofatumumab in the Real-World: Early 3 Months Data |
Patricia K. Coyle, MD1, Magdaliz Gorritz, MPH2, Rolin L Wade, RPh, MS2, Zifan Zhou, MS2, Yao Cao, MS2 and Chinmay Deshpande, PhD, BPharm3, (1)Department of Neurology, Stony Brook University, Stony Brook, NY, (2)IQVIA, Plymouth Meeting, PA, (3)Novartis Pharmaceuticals Corporation, East Hanover, NJ |
| 2021 | DMT54 | Poster | Disease-modifying Therapy |
Baseline MRI Predictors of Cognitive Processing Speed in Participants with Secondary Progressive Multiple Sclerosis from the Phase 3 Expand Study |
Ralph H.B. Benedict, PhD1, Iris-Katharina Penner, PhD2, Ludwig Kappos, MD3, Patrick Vermersch, MD, PhD4, Bruce A.C. Cree, MD, PhD, MAS5, Ralf Gold, MD6, Amit Bar-Or, MD7, Daniela Piani-Meier, PhD8, Shannon Ritter, MS8, Sophie Arnould, MSc8, Goeril Karlsson, PhD8, Frank Dahlke, MD8, Thomas Hach, MD8, Robert J. Fox, MD9 and Douglas L. Arnold, MD10,11, (1)Jacobs Multiple Sclerosis Center, University at Buffalo, Buffalo, NY, (2)Medical Faculty, Department of Neurology, Heinrich Heine University, COGITO Center for Applied Neurocognition and Neuropsychological Research, Dusseldorf, Germany, (3)Neurologic Clinic and Policlinic and Research Center for Clinical Neuroimmunology and Neuroscience, Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland, (4)FHU Imminent, Univ. Lille, Inserm UMR U1172 LilNCog, CHU Lille, Lille, France, (5)UCSF Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA, (6)Department of Neurology, St Josef-Hospital, Ruhr-University Bochum, Bochum, Germany, (7)Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, (8)Novartis Pharma AG, Basel, Switzerland, (9)Mellen Center for Treatment and Research in Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Cleveland, OH, (10)NeuroRx Research, Montreal, QC, Canada, (11)Brain Imaging Centre, Montreal Neurological Institute and Hospital, McGill University, Montreal, QC, Canada |
| 2021 | DMT55 | Poster | Disease-modifying Therapy |
Renato Mantegazza, MD1, Todd Levine, MD2, Celia Oreja-Guevara, MD3, Cynthia Carrillo-Infante, MD4, Eva Laudon-Meyer, MD PhD4, Shulian Shang, PhD4, Sean J Pittock, M.D.5 and James F. Howard Jr., MD6, (1)Fondazione IRCCS, Istituto Neurologico Carlo Besta, Milan, Italy, (2)Phoenix Neurological Associates, Phoenix, AZ, (3)Hospital Universitario Clinico San Carlos, Madrid, Spain, (4)Alexion Pharmaceuticals, Boston, MA, (5)Mayo Clinic, Rochester, MN, (6)Department of Neurology, University of North Carolina, Chapel Hill, NC |
| 2021 | DMT56 | Poster | Disease-modifying Therapy |
Long-Term Effect of Siponimod on MRI Outcomes in Secondary Progressive Multiple Sclerosis: Analyses from the Expand Study up to 5 Years |
Douglas L. Arnold, MD1,2, Ludwig Kappos, MD3, Patrick Vermersch, MD, PhD4, Ralf Gold, MD5, Amit Bar-Or, MD6, Gavin Giovannoni, MD, PhD7, Bruce A.C. Cree, MD, PhD, MAS8, Daniela Piani-Meier, PhD9, Shannon Ritter, MS10, Goeril Karlsson, PhD9, Frank Dahlke, MD9, Thomas Hach, MD9 and Robert J. Fox, MD11, (1)NeuroRx Research, Montreal, QC, Canada, (2)Brain Imaging Centre, Montreal Neurological Institute and Hospital, McGill University, Montreal, QC, Canada, (3)Neurologic Clinic and Policlinic and Research Center for Clinical Neuroimmunology and Neuroscience, Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland, (4)FHU Imminent, Univ. Lille, Inserm UMR U1172 LilNCog, CHU Lille, Lille, France, (5)Department of Neurology, St Josef-Hospital, Ruhr-University Bochum, Bochum, Germany, (6)Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, (7)Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, (8)UCSF Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA, (9)Novartis Pharma AG, Basel, Switzerland, (10)Novartis Pharmaceuticals Corporation, East Hanover, NJ, (11)Mellen Center for Treatment and Research in Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Cleveland, OH |
| 2021 | DMT57 | Poster | Disease-modifying Therapy |
Safety of Concurrent Administration of Ozanimod and Serotonergic Antidepressants in Patients with Relapsing Multiple Sclerosis |
| 2021 | DMT58 | Poster | Disease-modifying Therapy |
Rose-Marie M Jungquist, B.S.1, Martin Malik, B.S.2, Zoe Rimler, B.S.2, Elizabeth A Douglas, MPH1, Andrew J Bouley, M.D.1, Ellen S Lathi, M.D.1, Joshua D Katz, M.D.1 and Ilya Kister, MD3, (1)The Elliot Lewis Center for Multiple Sclerosis Care, Wellesley, MA, (2)Neurology, NYU Langone Health, New York, NY, (3)Multiple Sclerosis Comprehensive Care Center, Barnabas Health Medical Group, Livingston, NJ |
| 2021 | DMT59 | Poster | Disease-modifying Therapy |
Acapella: B-Cell Repletion in Ocrelizumab-Treated Patients |
Rosie M Jungquist, B.S., Elizabeth A Douglas, MPH, Andrew J Bouley, M.D., Ellen S Lathi, M.D. and Joshua D Katz, M.D., The Elliot Lewis Center for Multiple Sclerosis Care, Wellesley, MA |
| 2021 | DMT60 | Poster | Disease-modifying Therapy |
Clinical Outcomes in Patients with COVID-19 Infection during Phase IV Studies of Cladribine Tablets for Treatment of Multiple Sclerosis |
Radmila Karan, MD, Merck KGaA, Darmstadt, Germany, Darmstadt, Germany, Sanjeev Roy, MD, Merck KGaA, Darmstadt, Germany, Aubonne, Switzerland and Nektaria Alexandri, MD, MSc, Neurology and Immunology, Merck KGaA, Darmstadt, Germany, Darmstadt, Germany |
| 2021 | DMT61 | Poster | Disease-modifying Therapy |
Long-Term Efficacy and Safety of Eculizumab Monotherapy in AQP4+ Neuromyelitis Optica Spectrum Disorder |
Sean J Pittock, M.D.1, Kazuo Fujihara, MD2,3,4, Jacqueline Palace, DM5, Achim Berthele, MD6, Ho Jin Kim, MD, PhD7, Celia Oreja-Guevara, MD8, Ichiro Nakashima, MD, PhD3,9, Michael Levy, MD, PhD10,11, Shulian Shang, PhD12, Marcus Yountz, MD12, Larisa Miller, PharmD12, Roisin Armstrong, PhD12 and Dean Wingerchuk, M.D.13, (1)Mayo Clinic, Rochester, MN, (2)Southern TOHOKU Research Institute for Neuroscience (STRINS), Koriyama, Japan, (3)Tohoku University, Sendai, Japan, (4)Fukushima Medical University, Fukushima City, Japan, (5)John Radcliffe Hospital, Oxford, United Kingdom, (6)Klinikum rechts der Isar, School of Medicine, Technical University of Munich, Munich, Germany, (7)Research Institute and Hospital, National Cancer Center, Goyang, Korea, Republic of (South), (8)Hospital Universitario Clinico San Carlos, Madrid, Spain, (9)Tohoku Medical and Pharmaceutical University, Sendai, Japan, (10)Massachusetts General Hospital and Harvard Medical School, Boston, MA, (11)Johns Hopkins University, Baltimore, MD, (12)Alexion Pharmaceuticals, Boston, MA, (13)Mayo Clinic, Scottsdale, AZ |
| 2021 | DMT62 | Poster | Disease-modifying Therapy |
Safety and Effectiveness of Peginterferon Beta-1a in a Subgroup of African American Patients: Plegridy Observational Program Interim Analysis |
Sibyl Wray, MD1, Marco Salvetti, MD2, Gereon Nelles, MD3, Arman Altincatal, MS4, Nydjie Grimes, MPH, BA4, Achint Kumar, MBBS, MD4 and Maria L Naylor, PhD4, (1)Hope Neurology MS Center, Knoxville, TN, (2)Sapienza University, S. Andrea Hospital, Rome, Italy, (3)Neurology, NeuroMed Campus Hohenlind, Cologne, Germany, (4)Biogen, Cambridge, MA |
| 2021 | DMT63 | Poster | Disease-modifying Therapy |
Comparable Ofatumumab Treatment Outcomes in Patients across Racial/Ethnic Groups in the Asclepios I/II and Apolitos Studies |
Silvia Delgado, MD1, Mitzi J Williams, MD2, Morten Bagger, PhD3, Gordon Graham, PhD3, Etienne Pigeolet, PhD3, Huixin Yu, PhD3, Dieter A. Haering, PhD3, Roman Willi, PhD3, Cecile Kerloeguen, MSc3, Chao Xu, PhD4, Masaru Hirano, PhD5, Dee Stoneman, MPharm3, Wendy Su, PhD6, Krishnan Ramanathan, PhD3 and Jin Nakahara, MD, PhD7, (1)Neurology, University of Miami Miller School of Medicine, Miami, FL, (2)Joi Life Wellness MS Center, Atlanta, GA, (3)Novartis Pharma AG, Basel, Switzerland, (4)China Novartis Institute of Biomedical Research, Shanghai, China, (5)Novartis Pharmaceutics, K.K., Tokyo, Japan, (6)Autoimmune, TG Therapeutics, Inc, New York, NY, (7)Department of Neurology, Keio University School of Medicine, Tokyo, Japan |
| 2021 | DMT64 | Poster | Disease-modifying Therapy |
The Benefits of Azathioprine in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: A Systematic Review and Meta-Analysis |
Smathorn Thakolwiboon, MD1, Hannah Zhao-Fleming, MD, PhD2, Amputch Karukote, MD1 and Mirla Avila, MD1, (1)Neurology, Texas Tech University Health Sciences Center, Lubbock, TX, (2)Neurology, Mayo Clinic, Rochester, MN |
| 2021 | DMT65 | Poster | Disease-modifying Therapy |
Sonia Afsari, MD1, Alyssa Henry, MD1, Giancarlo Comi, MD2, Marla C. Dubinsky, MD3, Uma Mahadevan, MD4, Lorna Charles, MD1, C. Janneke van der Woude, MD, PhD5 and Krzysztof Selmaj, MD6, (1)Bristol Myers Squibb, Princeton, NJ, (2)University Vita-Salute San Raffaele, Milan, Italy, (3)Icahn School of Medicine, Mount Sinai, NY, (4)University of California San Francisco, San Francisco, CA, (5)Erasmus MC, Rotterdam, Netherlands, (6)Center for Neurology, Lodz, Poland |
| 2021 | DMT66 | Poster | Disease-modifying Therapy |
Safety and Efficacy of Siponimod in Patients with Active Secondary Progressive Multiple Sclerosis Identifying As Hispanic from the Expand Study |
Stanley Cohan, MD, PhD1, Le H. Hua, MD2, Amit Bar-Or, MD3, Fred D. Lublin, MD4, Xiangyi Meng, PhD5, Gina Mavrikis Cox, PhD5, Patricia K. Coyle, MD6 and Robert J. Fox, MD7, (1)Providence Brain and Spine Institute, and Providence Multiple Sclerosis Center, Providence Health & Services, Portland, OR, (2)Lou Ruvo Center for Brain Health, Las Vegas, NV, (3)Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, (4)Icahn School of Medicine at Mount Sinai, New York, NY, (5)Novartis Pharmaceuticals Corporation, East Hanover, NJ, (6)Multiple Sclerosis Comprehensive Care Center, Stony Brook University, Stony Brook, NY, (7)Mellen Center for Treatment and Research in Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Cleveland, OH |
| 2021 | DMT67 | Poster | Disease-modifying Therapy |
A Single Center Retrospective Analysis of Insurance Policy Impact on the Choice of Multiple Sclerosis Disease Modifying Therapies |
Stephanie L Reyes, BA, University of Michigan Medical School, Ann Arbor, MI and Andrew Romeo, MD, Neurology, University of Michigan, Ann Arbor, MI |